COVID-19 Drug Development

被引：19
作者：
Kim, Seungtaek [1 ]
机构：
[1] Inst Pasteur Korea, Zoonot Virus Lab, Seongnam 13488, South Korea
来源：
JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY | 2022年 / 32卷 / 01期
基金：
新加坡国家研究基金会;
关键词：
COVID-19; SARS-CoV-2; drug repurposing; monoclonal antibody; convalescent plasma;
D O I：
10.4014/jmb.2110.10029
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.
引用
收藏
页码：1 / 5
页数：5
相关论文
共 50 条
  • [21] Psychotropic drug repurposing for COVID-19: a systematic review
    Isayeva, U.
    Fico, G.
    Gomes-Da-Costa, S.
    Sague Villavella, M.
    Gimenez, A.
    Manchia, M.
    Murru, A.
    [J]. EUROPEAN PSYCHIATRY, 2022, 65 : S337 - S337
  • [22] Graph Representation Learning for Covid-19 Drug Repurposing
    Boutorh, Aicha
    Marref, Kaouter
    Dehiri, Naamat Ellah
    [J]. ADVANCES IN COMPUTING SYSTEMS AND APPLICATIONS, 2022, 513 : 61 - 72
  • [23] An effective drug against COVID-19: reality or dream?
    Yaghoubi, Atieh
    Amel Jamehdar, Saeid
    Movaqar, Aref
    Milani, Nasrin
    Soleimanpour, Saman
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (04) : 505 - 518
  • [24] Potential drug development and therapeutic approaches for clinical intervention in COVID-19
    Dowarah, Jayanta
    Marak, Brilliant N.
    Yadav, Umesh Chand Singh
    Singh, Ved Prakash
    [J]. BIOORGANIC CHEMISTRY, 2021, 114
  • [25] Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
    Qu, Na
    Hui, Zongguang
    Shen, Zhixin
    Kan, Chengxia
    Hou, Ningning
    Sun, Xiaodong
    Han, Fang
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [26] Drug development process and COVID-19 pandemic: Flourishing era of outsourcing
    Wasan, Himika
    Singh, Devendra
    Reeta, K. H.
    Gupta, Pooja
    Gupta, Yogendra Kumar
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2022, 54 (05) : 364 - 372
  • [27] Can the COVID-19 Pandemic Disrupt the Current Drug Development Practices?
    Won, Jung-Hyun
    Lee, Howard
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [28] Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs
    Shi, Jun
    Xiao, Yubo
    Zhang, Yiting
    Geng, Donghao
    Cong, Danhua
    Shi, Kevin X.
    Knapp, Richard J.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (05) : 2170 - 2185
  • [29] TARGET BASED PHARMACOLOGICAL APPROACHES FOR DRUG DEVELOPMENT AGAINST NOVEL CORONA VIRUS (COVID-19)
    Hoda, Quaisul
    Fatma, Askary
    Pahwa, Shilpa
    Gupta, Chitra
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (11): : 5284 - 5289
  • [30] COVID-19 Drug Treatment in China
    Fan L.
    Jiang S.
    Yang X.
    Wang Z.
    Yang C.
    [J]. Current Pharmacology Reports, 2020, 6 (4) : 146 - 154
12345